Zimmer Biomet Holdings, Inc. (NYSE:ZBH)‘s stock had its “hold” rating reaffirmed by stock analysts at Stifel Nicolaus in a report issued on Friday. They presently have a $120.00 target price on the medical equipment provider’s stock. Stifel Nicolaus’ price objective would indicate a potential upside of 9.63% from the company’s current price.

A number of other analysts have also recently issued reports on the company. Jefferies Group LLC reissued a “buy” rating and set a $136.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday. Morgan Stanley lowered their target price on Zimmer Biomet Holdings from $146.00 to $136.00 and set an “overweight” rating for the company in a research note on Thursday. BMO Capital Markets lowered their target price on Zimmer Biomet Holdings from $140.00 to $135.00 and set an “outperform” rating for the company in a research note on Thursday. Piper Jaffray Companies cut Zimmer Biomet Holdings from an “overweight” rating to a “neutral” rating in a research note on Thursday. Finally, SunTrust Banks, Inc. set a $136.00 target price on Zimmer Biomet Holdings and gave the stock a “buy” rating in a research note on Wednesday. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Zimmer Biomet Holdings has a consensus rating of “Hold” and a consensus price target of $134.75.

Zimmer Biomet Holdings (NYSE:ZBH) traded down $5.63 during midday trading on Friday, reaching $109.46. The company had a trading volume of 3,317,008 shares, compared to its average volume of 1,446,411. The firm has a market capitalization of $22,710.64, a P/E ratio of 13.92 and a beta of 1.17.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same period in the previous year, the company posted $1.79 earnings per share. Zimmer Biomet Holdings’s revenue for the quarter was down .8% compared to the same quarter last year. equities analysts expect that Zimmer Biomet Holdings will post 8.03 earnings per share for the current fiscal year.

WARNING: This piece was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/03/zimmer-biomet-holdings-inc-zbh-earns-hold-rating-from-stifel-nicolaus.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bessemer Group Inc. boosted its holdings in shares of Zimmer Biomet Holdings by 14.6% in the 3rd quarter. Bessemer Group Inc. now owns 4,925 shares of the medical equipment provider’s stock valued at $577,000 after buying an additional 628 shares during the last quarter. Obermeyer Wood Investment Counsel Lllp raised its stake in Zimmer Biomet Holdings by 1.0% in the 3rd quarter. Obermeyer Wood Investment Counsel Lllp now owns 248,955 shares of the medical equipment provider’s stock valued at $29,150,000 after acquiring an additional 2,431 shares during the period. Exchange Capital Management Inc. raised its stake in Zimmer Biomet Holdings by 3,324.0% in the 3rd quarter. Exchange Capital Management Inc. now owns 5,136 shares of the medical equipment provider’s stock valued at $601,000 after acquiring an additional 4,986 shares during the period. Fiduciary Trust Co. raised its stake in Zimmer Biomet Holdings by 5.7% in the 3rd quarter. Fiduciary Trust Co. now owns 11,868 shares of the medical equipment provider’s stock valued at $1,390,000 after acquiring an additional 637 shares during the period. Finally, Oregon Public Employees Retirement Fund raised its stake in Zimmer Biomet Holdings by 2.9% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 21,484 shares of the medical equipment provider’s stock valued at $2,516,000 after acquiring an additional 615 shares during the period. 85.26% of the stock is owned by institutional investors.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.